Leadership & Pay ·
On August 5, 2026, Apimeds Pharmaceuticals US, Inc. appointed Dr. Christopher Kim as its Chief Scientific Officer…
APUSApimeds Pharmaceuticals US, Inc.
On August 5, 2026, Apimeds Pharmaceuticals US, Inc. appointed Dr. Christopher Kim as its Chief Scientific Officer, effective immediately. In this role, Dr. Kim will lead the scientific, clinical, and regulatory development of the company's APITOX program, overseeing research, clinical strategy, and regulatory engagement to advance the asset toward commercialization. The appointment provides continuity in leadership for a program with which Dr. Kim has been closely associated for many years. Apimeds Pharmaceuticals US, Inc. operates in the pharmaceutical industry, focusing on drug development.